FULC - Fulcrum Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
Total Revenue
0
0
0
0
Operating Expenses
Research Development
71,072
71,072
25,184
18,494
Selling General and Administrative
13,145
13,145
8,314
4,499
Total Operating Expenses
84,217
84,217
33,498
22,993
Operating Income or Loss
-84,217
-84,217
-33,498
-22,993
Total Other Income/Expenses Net
29
29
392
28
Income Before Tax
-82,677
-82,677
-32,588
-22,964
Income from Continuing Operations
-82,677
-82,677
-32,588
-22,964
Net Income
-82,677
-82,677
-32,588
-22,964
Net Income available to common shareholders
-89,805
-89,805
-32,588
-25,371
Basic EPS
-
-8.13
-2.98
-2.32
Diluted EPS
-
-8.13
-2.98
-2.32
Basic Average Shares
-
11,046
10,951
10,951
Diluted Average Shares
-
11,046
10,951
10,951
EBITDA
-
-82,164
-32,153
-22,278